

Entacapone (sodium salt)

Catalog No: tcsc2022



Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1047659-02-8

Formula:

$C_{14}H_{14}N_3NaO_5$

Pathway:

Neuronal Signaling;Metabolic Enzyme/Protease

Target:

COMT;COMT

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:

327.27

Product Description

Entacapone is a specific, potent, peripherally acting catechol-O-methyltransferase (COMT) inhibitor with IC50 of 151 nM for PD treatment.


IC50 Value: 151 nM

Target: COMT

in vitro: Entacapone inhibits catechol-O-methyltransferase(COMT) with similar IC50 in different tissues including liver, duodenum, kidney and lung, but entacapone is more active than tolcapone in those tissues. Entacapone (

in vivo: Levodopa/carbidopa/entacapone has been shown to improve the pharmacokinetic profile of levodopa and provide superior symptomatic control compared with conventional levodopa/dopa decarboxylase inhibitor therapy. We report four case histories describing clinical experience of using levodopa/carbidopa/entacapone 200/50/200 mg, one of the latest doses of this formulation, in a range of patients with Parkinson's disease. These cases illustrate that levodopa/carbidopa/entacapone 200/50/200 mg provides improvements in symptomatic control.

Clinical trial: The combination product carbidopa/levodopa/entacapone (CLE) was approved in 2003 for the treatment of PD patients.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!